Neuberger Berman Group
NKTR icon

Neuberger Berman Group’s Nektar Therapeutics NKTR Stock Holding History

Neuberger Berman Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,368
Closed -$19.1K – 2028
2024
Q4 		$19.1K Buy
1,368
+282
+26% +$4.97K ﹤0.01% 1912
2024
Q3 		$21.2K Buy
+1,086
New +$20.7K ﹤0.01% 1897
2024
Q1 		– Sell
-975
Closed -$8.26K – 1888
2023
Q4 		$8.26K Buy
975
+214
+28% +$1.62K ﹤0.01% 1853
2023
Q3 		$6.8K Buy
761
+79
+12% +$760 ﹤0.01% 1796
2023
Q2 		$5.88K Buy
+682
New +$7.27K ﹤0.01% 1793
2018
Q2 		– Sell
-160
Closed -$255K – 1736
2018
Q1 		$255K Sell
160
-17,373
-99% -$22.4M ﹤0.01% 1534
2017
Q4 		$15.7M Buy
17,533
+2,540
+17% +$1.5M 0.02% 689
2017
Q3 		$5.4M Buy
+14,993
New +$4.69M 0.01% 843

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Neuberger Berman Group's NKTR Position: Q1 2025 in Review

Neuberger Berman Group sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 1,368 shares — an estimated $19.1K sold.

Neuberger Berman Group first reported a position in NKTR in Q3 2017 and held it in 8 quarters. The position peaked at $15.7M in Q4 2017. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

  • Neuberger Berman Group reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Neuberger Berman Group sold 1,368 Nektar Therapeutics shares in Q1 2025, an estimated $19.1K.
  • Neuberger Berman Group first reported a position in Nektar Therapeutics in Q3 2017 and held it in 8 quarters.
  • Neuberger Berman Group's Nektar Therapeutics position peaked at $15.7M in Q4 2017.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Neuberger Berman Group's 13F filing for Q1 2025, filed 13 May 2025.